Eli Lilly (LLY)

Eli Lilly's valuation looks far more attractive now than it did even a year ago.

These stocks have been struggling over the past year, but their growth days are far from over.

The Street is bullish on this biotech's prospects, but is the sentiment justified?

Eli Lilly is coming off an impressive first-quarter performance, with sales soaring by 56%.

Eli Lilly stock toppled Monday after a patient taking its new weight-loss pill, Foundayo, experienced liver failure.

Lilly's weight loss drugs have been delivering blockbuster revenue.

Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) will be announcing earnings results this Tuesday before the bell. Here’s what to loo...

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors should know. Pfizer beat analys...

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Tuesday after market hours. Here’s what you need to know. Jazz Pharmaceut...

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results this Tuesday after the bell. Here’s what to look ...

A new weight loss pill is expanding the pharmaceutical leader's already massive market opportunity.

Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.

Veeva Systems stock pops following S&P 500 inclusion announcement.

Major M&A deals this week include: Eli Lilly buys Profluent for $2.2 billion, Lazard buys Campbell Lutyens, FreshRealm bankruptcy.

The prescription data collected for Eli Lilly's new weight-loss pill, Foundayo, is flawed, analysts said Friday.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.3% in the morning session after the stock continued to rally as the comp...

Eli Lilly stock jumps on strong Q1 performance numbers, with its GLP-1s leading the chart.

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 55.5% year on year to $19...

Gary Black calls Eli Lilly's valuation 'compelling' as Q1 earnings soar, driven by the consumer 'love affair' with GLP-1 weight loss drugs.

Eli Lilly stock rallies as GLP-1 sales drive a 56% year-on-year increase in Q1 revenue. Jim Cramer recommends buying LLY shares as the weight-loss addressable market is truly huge.